πŸ‡ΊπŸ‡Έ FDA
Patent

US 10081624

Heterocyclic compound

granted A61KA61K31/4245A61K31/454

Quick answer

US patent 10081624 (Heterocyclic compound) held by Takeda Pharmaceutical Company Limited expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4245, A61K31/454, A61K31/4709, A61K31/4725